{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:06:08Z","timestamp":1775840768188,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T00:00:00Z","timestamp":1728086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009828","name":"Cancer Research Wales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009828","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C7838\/A25173"],"award-info":[{"award-number":["C7838\/A25173"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C36442\/A27838"],"award-info":[{"award-number":["C36442\/A27838"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000383","name":"HEFCW","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000383","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,11,30]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pancreatic ductal adenocarcinoma (PDAC) represent an unmet clinical need. Approximately 90% of PDACs express high levels of \u03b1v\u03b26 integrin. We have previously described Ad5<jats:sub>NULL<\/jats:sub>-A20, an adenovirus vector with ablated native means of cell entry and retargeted to \u03b1v\u03b26 integrin by incorporation of an A20 peptide.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Here, we incorporate suicide genes FCY1 and FCU1 encoding for cytosine deaminase (CDase) or a combination of CDase and UPRTase, capable of catalysing a non-toxic prodrug, 5-FC into the chemotherapeutic 5-FU and downstream metabolites, into replication-deficient Ad5 and Ad5<jats:sub>NULL<\/jats:sub>-A20.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We show that Ad5<jats:sub>NULL<\/jats:sub>-A20 enables the transfer of suicide genes to \u03b1v\u03b26 integrin-positive PDAC cells which, in combination with 5-FC, results in cell death in vitro which is further mediated by a bystander effect in non-transduced cells. Intratumoural delivery of Ad5<jats:sub>NULL<\/jats:sub>-A20.FCU1 in combination with intraperitoneal delivery of 5-FC further results in tumour growth inhibition in a cell line xenograft in vivo. Using clinically-relevant 3D organoid models, we show selective transduction and therapeutic efficacy of FCU1 transgenes in combination with 5-FC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Taken together these data provide the preclinical rationale for combined Ad5<jats:sub>NULL<\/jats:sub>-A20.FCU1 plus 5-FC as a promising targeted therapy to mediate \u201cin-tumour chemotherapy\u201d and merits further investigation for the treatment of PDAC patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-024-02869-3","type":"journal-article","created":{"date-parts":[[2024,10,5]],"date-time":"2024-10-05T19:01:45Z","timestamp":1728154905000},"page":"1694-1706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The \u03b1v\u03b26 integrin specific virotherapy, Ad5NULL-A20.FCU1, selectively delivers potent \u201cin-tumour\u201d chemotherapy to pancreatic ductal adenocarcinoma"],"prefix":"10.1038","volume":"131","author":[{"given":"Luned M.","family":"Badder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie S.","family":"Meniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahulena","family":"Maru\u0161kov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3842-2383","authenticated-orcid":false,"given":"Beatriz","family":"Salvador-Barbero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca J.","family":"Bayliss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-4916","authenticated-orcid":false,"given":"Toby J.","family":"Phesse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1012-0896","authenticated-orcid":false,"given":"Catherine","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-1761","authenticated-orcid":false,"given":"Alan L.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,5]]},"reference":[{"key":"2869_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-019-1345-6","volume":"14","author":"M Orth","year":"2019","unstructured":"Orth M, Metzger P, Gerum S, Mayerle J, Schneider G, Belka C, et al. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches. Radiat Oncol. 2019;14:141.","journal-title":"Radiat Oncol"},{"key":"2869_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.22","volume":"2","author":"J Kleeff","year":"2016","unstructured":"Kleeff J, Korc M, Apte M, La Vecchia C, Johnson CD, Biankin AV, et al. Pancreatic cancer. Nat Rev Dis Prim. 2016;2:16022.","journal-title":"Nat Rev Dis Prim"},{"key":"2869_CR3","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao1641","volume":"10","author":"M-C Bourgeois-Daigneault","year":"2018","unstructured":"Bourgeois-Daigneault M-C, Roy DG, Aitken AS, El Sayes N, Martin NT, Varette O, et al. Neoadjuvant oncolytic virotherapy before surgery sensitizes triple-negative breast cancer to immune checkpoint therapy. Sci Transl Med. 2018;10:eaao1641.","journal-title":"Sci Transl Med"},{"key":"2869_CR4","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.3390\/cancers12113327","volume":"12","author":"TG Cunliffe","year":"2020","unstructured":"Cunliffe TG, Bates EA, Parker AL. Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies. Cancers. 2020;12:3327.","journal-title":"Cancers"},{"key":"2869_CR5","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1158\/1078-0432.CCR-09-2974","volume":"16","author":"JD Dias","year":"2010","unstructured":"Dias JD, Liikanen I, Guse K, Foloppe J, Sloniecka M, Diaconu I, et al. Targeted chemotherapy for head and neck cancer with a chimeric oncolytic adenovirus coding for bifunctional suicide protein FCU1. Clin Cancer Res. 2010;16:2540\u20139.","journal-title":"Clin Cancer Res"},{"key":"2869_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/ijc.29442","volume":"137","author":"K Hammer","year":"2015","unstructured":"Hammer K, Kazcorowski A, Liu L, Behr M, Schemmer P, Herr I, et al. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells. Int J Cancer. 2015;137:978\u201390.","journal-title":"Int J Cancer"},{"key":"2869_CR7","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ygyno.2007.09.013","volume":"108","author":"M Raki","year":"2008","unstructured":"Raki M, S\u00e4rkioja M, Desmond RA, Chen DT, B\u00fctzow R, Hemminki A, et al. Oncolytic adenovirus Ad5\/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol. 2008;108:166\u201372.","journal-title":"Gynecol Oncol"},{"key":"2869_CR8","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1182\/blood-2006-04-008532","volume":"108","author":"AL Parker","year":"2006","unstructured":"Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, Denby L, et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood. 2006;108:2554\u201361.","journal-title":"Blood"},{"key":"2869_CR9","doi-asserted-by":"publisher","first-page":"6009","DOI":"10.3390\/v7112923","volume":"7","author":"H Uusi-Kerttula","year":"2015","unstructured":"Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker AL. Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses. 2015;7:6009\u201342.","journal-title":"Viruses"},{"key":"2869_CR10","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","volume":"275","author":"JM Bergelson","year":"1997","unstructured":"Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320\u20133.","journal-title":"Science"},{"key":"2869_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","volume":"73","author":"TJ Wickham","year":"1993","unstructured":"Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993;73:309\u201319.","journal-title":"Cell"},{"key":"2869_CR12","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.addr.2005.01.007","volume":"57","author":"CB Coyne","year":"2005","unstructured":"Coyne CB, Bergelson JM. CAR: a virus receptor within the tight junction. Adv drug Deliv Rev. 2005;57:869\u201382.","journal-title":"Adv drug Deliv Rev"},{"key":"2869_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2008.01.016","volume":"132","author":"SN Waddington","year":"2008","unstructured":"Waddington SN, McVey JH, Bhella D, Parker AL, Barker K, Atoda H, et al. Adenovirus serotype 5 hexon mediates liver gene transfer. Cell. 2008;132:397\u2013409.","journal-title":"Cell"},{"key":"2869_CR14","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-18-1089","volume":"24","author":"H Uusi-Kerttula","year":"2018","unstructured":"Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, et al. Ad5(NULL)-A20: A Tropism-Modified, \u03b1v\u03b26 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies. Clin Cancer Res. 2018;24:4215\u201324.","journal-title":"Clin Cancer Res"},{"key":"2869_CR15","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/v13050864","volume":"13","author":"JA Davies","year":"2021","unstructured":"Davies JA, Marlow G, Uusi-Kerttula HK, Seaton G, Piggott L, Badder LM, et al. Efficient Intravenous Tumor Targeting Using the \u03b1v\u03b26 Integrin-Selective Precision Virotherapy Ad5(NULL)-A20. Viruses. 2021;13:864.","journal-title":"Viruses"},{"key":"2869_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/path.5320","volume":"249","author":"CS Reader","year":"2019","unstructured":"Reader CS, Vallath S, Steele CW, Haider S, Brentnall A, Desai A, et al. The integrin \u03b1v\u03b26 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. J Pathol. 2019;249:332\u201342.","journal-title":"J Pathol"},{"key":"2869_CR17","doi-asserted-by":"publisher","DOI":"10.1177\/1536012117709384","volume":"16","author":"K Steiger","year":"2017","unstructured":"Steiger K, Schlitter A-M, Weichert W, Esposito I, Wester H-J, Notni J. Perspective of \u03b1v\u03b26-Integrin Imaging for Clinical Management of Pancreatic Carcinoma and Its Precursor Lesions. Mol Imaging. 2017;16:1536012117709384.","journal-title":"Mol Imaging"},{"key":"2869_CR18","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/nrc1074","volume":"3","author":"DB Longley","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3:330\u20138.","journal-title":"Nat Rev Cancer"},{"key":"2869_CR19","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1242\/dev.129.10.2447","volume":"129","author":"G Gu","year":"2002","unstructured":"Gu G, Dubauskaite J, Melton DA. Direct evidence for the pancreatic lineage: NGN3+ cells are islet progenitors and are distinct from duct progenitors. Development. 2002;129:2447\u201357.","journal-title":"Development"},{"key":"2869_CR20","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1101\/gad.943001","volume":"15","author":"EL Jackson","year":"2001","unstructured":"Jackson EL, Willis N, Mercer K, Bronson RT, Crowley D, Montoya R, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 2001;15:3243\u20138.","journal-title":"Genes Dev"},{"key":"2869_CR21","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2004.11.004","volume":"119","author":"KP Olive","year":"2004","unstructured":"Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847\u201360.","journal-title":"Cell"},{"key":"2869_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/eji.200636745","volume":"37","author":"H Luche","year":"2007","unstructured":"Luche H, Weber O, Nageswara Rao T, Blum C, Fehling HJ. Faithful activation of an extra-bright red fluorescent protein in \u201cknock-in\u201d Cre-reporter mice ideally suited for lineage tracing studies. Eur J Immunol. 2007;37:43\u201353.","journal-title":"Eur J Immunol"},{"key":"2869_CR23","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.ccell.2020.01.007","volume":"37","author":"B Salvador-Barbero","year":"2020","unstructured":"Salvador-Barbero B, \u00c1lvarez-Fern\u00e1ndez M, Zapatero-Solana E, El Bakkali A, Men\u00e9ndez MDC, L\u00f3pez-Casas PP, et al. CDK4\/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Cancer Cell. 2020;37:340\u201353.e6.","journal-title":"Cancer Cell"},{"key":"2869_CR24","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1016\/j.cub.2021.03.094","volume":"31","author":"W Hill","year":"2021","unstructured":"Hill W, Zaragkoulias A, Salvador-Barbero B, Parfitt GJ, Alatsatianos M, Padilha A, et al. EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neighbors in the adult pancreas. Curr Biol. 2021;31:2550\u201360.e5.","journal-title":"Curr Biol"},{"key":"2869_CR25","doi-asserted-by":"crossref","unstructured":"Salvador-Barbero B, Alatsatianos M, Morton JP, Sansom OJ, Hogan C. Oncogenic KRAS cells use Wnt signalling and cell dormancy to override homeostatic cell elimination mechanisms in adult pancreas. bioRxiv. 2024. https:\/\/www.biorxiv.org\/content\/10.1101\/2024.02.13.579930v1.","DOI":"10.1101\/2024.02.13.579930"},{"key":"2869_CR26","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/sj.cgt.7701098","volume":"15","author":"P Erbs","year":"2008","unstructured":"Erbs P, Findeli A, Kintz J, Cordier P, Hoffmann C, Geist M, et al. Modified vaccinia virus Ankara as a vector for suicide gene therapy. Cancer Gene Ther. 2008;15:18\u201328.","journal-title":"Cancer Gene Ther"},{"key":"2869_CR27","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1038\/bjc.2013.509","volume":"109","author":"M Reeh","year":"2013","unstructured":"Reeh M, Bockhorn M, G\u00f6rgens D, Vieth M, Hoffmann T, Simon R, et al. Presence of the Coxsackievirus and Adenovirus Receptor (CAR) in human neoplasms: a multitumour array analysis. Br J Cancer. 2013;109:1848\u201358.","journal-title":"Br J Cancer"},{"key":"2869_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","volume":"7","author":"SR Hingorani","year":"2005","unstructured":"Hingorani SR, Wang L, Multani AS, Combs C, Deramaudt TB, Hruban RH, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell. 2005;7:469\u201383.","journal-title":"Cancer Cell"},{"key":"2869_CR29","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.cell.2014.12.021","volume":"160","author":"F Boj Sylvia","year":"2015","unstructured":"Boj Sylvia F, Hwang C-I, Baker Lindsey A, Chio Iok In C, Engle Dannielle D, Corbo V, et al. Organoid Models of Human and Mouse Ductal Pancreatic Cancer. Cell. 2015;160:324\u201338.","journal-title":"Cell"},{"key":"2869_CR30","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.3390\/cancers12102750","volume":"12","author":"P-O Frappart","year":"2020","unstructured":"Frappart P-O, Hofmann TG. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine. Cancers. 2020;12:2750.","journal-title":"Cancers"},{"key":"2869_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/cpcb.66","volume":"82","author":"J Clinton","year":"2019","unstructured":"Clinton J, McWilliams-Koeppen P. Initiation, Expansion, and Cryopreservation of Human Primary Tissue-Derived Normal and Diseased Organoids in Embedded Three-Dimensional Culture. Curr Protoc Cell Biol. 2019;82:e66.","journal-title":"Curr Protoc Cell Biol"},{"key":"2869_CR32","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/gt.2008.82","volume":"15","author":"J Foloppe","year":"2008","unstructured":"Foloppe J, Kintz J, Futin N, Findeli A, Cordier P, Schlesinger Y, et al. Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus. Gene Ther. 2008;15:1361\u201371.","journal-title":"Gene Ther"},{"key":"2869_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omto.2017.08.003","volume":"7","author":"M Ricordel","year":"2017","unstructured":"Ricordel M, Foloppe J, Pichon C, Sfrontato N, Antoine D, Tosch C, et al. Cowpox Virus: A New and Armed Oncolytic Poxvirus. Mol Ther Oncolytics. 2017;7:1\u201311.","journal-title":"Mol Ther Oncolytics"},{"key":"2869_CR34","doi-asserted-by":"publisher","first-page":"826302","DOI":"10.3389\/fmolb.2022.826302","volume":"9","author":"ME Carter","year":"2022","unstructured":"Carter ME, Hartkopf AD, Wagner A, Volmer LL, Brucker SY, Berchtold S, et al. A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy. Front Mol Biosci. 2022;9:826302.","journal-title":"Front Mol Biosci"},{"key":"2869_CR35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1158\/0008-5472.CAN-07-2307","volume":"68","author":"LA Van Aarsen","year":"2008","unstructured":"Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage DJ, et al. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res. 2008;68:561\u201370.","journal-title":"Cancer Res"},{"key":"2869_CR36","first-page":"100023","volume":"5","author":"A Meecham","year":"2020","unstructured":"Meecham A, Marshall JF. The ITGB6 gene: its role in experimental and clinical biology. Gene X. 2020;5:100023.","journal-title":"Gene X"},{"key":"2869_CR37","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1242\/jcs.108.6.2241","volume":"108","author":"JM Breuss","year":"1995","unstructured":"Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. J Cell Sci. 1995;108:2241\u201351.","journal-title":"J Cell Sci"},{"key":"2869_CR38","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3390\/cancers9090110","volume":"9","author":"S Raab-Westphal","year":"2017","unstructured":"Raab-Westphal S, Marshall JF, Goodman SL. Integrins as Therapeutic Targets: Successes and Cancers. Cancers. 2017;9:110.","journal-title":"Cancers"},{"key":"2869_CR39","doi-asserted-by":"publisher","first-page":"e1006596","DOI":"10.1371\/journal.pcbi.1006596","volume":"15","author":"DMA Gendoo","year":"2019","unstructured":"Gendoo DMA, Denroche RE, Zhang A, Radulovich N, Jang GH, Lemire M, et al. Whole genomes define concordance of matched primary, xenograft, and organoid models of pancreas cancer. PLOS Comput Biol. 2019;15:e1006596.","journal-title":"PLOS Comput Biol"},{"key":"2869_CR40","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1158\/2159-8290.CD-18-0349","volume":"8","author":"H Tiriac","year":"2018","unstructured":"Tiriac H, Belleau P, Engle DD, Plenker D, Desch\u00eanes A, Somerville TDD, et al. Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov. 2018;8:1112\u201329.","journal-title":"Cancer Discov"},{"key":"2869_CR41","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.stem.2017.12.009","volume":"22","author":"T Seino","year":"2018","unstructured":"Seino T, Kawasaki S, Shimokawa M, Tamagawa H, Toshimitsu K, Fujii M, et al. Human Pancreatic Tumor Organoids Reveal Loss of Stem Cell Niche Factor Dependence during Disease Progression. Cell Stem Cell. 2018;22:454\u201367. e6","journal-title":"Cell Stem Cell"},{"key":"2869_CR42","doi-asserted-by":"publisher","first-page":"e135544","DOI":"10.1172\/jci.insight.135544","volume":"5","author":"L Huang","year":"2020","unstructured":"Huang L, Bockorny B, Paul I, Akshinthala D, Frappart PO, Gandarilla O, et al. PDX-derived organoids model in vivo drug response and secrete biomarkers. JCI Insight. 2020;5:e135544.","journal-title":"JCI Insight"},{"key":"2869_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102786","volume":"56","author":"G Raimondi","year":"2020","unstructured":"Raimondi G, Mato-Berciano A, Pascual-Sabater S, Rovira-Rigau M, Cuatrecasas M, Fondevila C, et al. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses. EBioMedicine. 2020;56:102786.","journal-title":"EBioMedicine"},{"key":"2869_CR44","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jviromet.2018.12.017","volume":"265","author":"A Rosellini","year":"2019","unstructured":"Rosellini A, Freer G, Quaranta P, Dovere V, Menichini M, Maggi F, et al. Enhanced in vitro virus expression using 3-dimensional cell culture spheroids for infection. J Virol Methods. 2019;265:99\u2013104.","journal-title":"J Virol Methods"},{"key":"2869_CR45","doi-asserted-by":"publisher","first-page":"440","DOI":"10.3390\/cancers13030440","volume":"13","author":"TND Pham","year":"2021","unstructured":"Pham TND, Shields MA, Spaulding C, Principe DR, Li B, Underwood PW, et al. Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies. Cancers. 2021;13:440.","journal-title":"Cancers"},{"key":"2869_CR46","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1177\/002215540205001010","volume":"50","author":"N Ahmed","year":"2002","unstructured":"Ahmed N, Riley C, Rice GE, Quinn MA, Baker MS. \u03b1v\u03b26 Integrin-A Marker for the Malignant Potential of Epithelial Ovarian Cancer. J Histochem Cytochem. 2002;50:1371\u20139.","journal-title":"J Histochem Cytochem"},{"key":"2869_CR47","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clon.2007.09.008","volume":"20","author":"ZY Zhang","year":"2008","unstructured":"Zhang ZY, Xu KS, Wang JS, Yang GY, Wang W, Wang JY, et al. Integrin \u03b1\u03bd\u03b26 Acts as a Prognostic Indicator in Gastric Carcinoma. Clin Oncol. 2008;20:61\u20136.","journal-title":"Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02869-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02869-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02869-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T07:05:29Z","timestamp":1731481529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02869-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,5]]},"references-count":47,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,11,30]]}},"alternative-id":["2869"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02869-3","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,5]]},"assertion":[{"value":"6 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"LMB, JAD and ALP are named inventors on a patent application related to the Ad5<sub>NULL<\/sub>-A20.FCU1 platform. Additionally, ALP is Founder and Chief Scientific Officer of Trocept Therapeutics, a subsidiary of Accession Therapeutics Ltd. Other authors have no conflicts to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}